Larimar Therapeutics Inc
(STU:ZA71)
€
3.72
+0.060 (+1.64%)
Market Cap: 393.15 Mil
Enterprise Value: 261.96 Mil
PE Ratio: 0
PB Ratio: 3.56
GF Score: 34/100 Larimar Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 14, 2026 / 05:00PM GMT
Release Date Price:
€2.92
(+2.10%)
Henry Jiang
JPMorgan Chase & Co - Analyst
My name is, Thanking team here at JP Morgan and it's my pleasure to introduce Laramar Therapeutics today. Presenting today will be Doctor Carol Ben Maiman, President and CEO of Larimar. Just a quick note, we'll have time for Q&A after the presentation, so please wait until then for any questions and we'll get you a microphone. But without further ado, I'll turn it over to you, Carol.
Carole Ben;Maimon
Larimar Therapeutics Inc - President, Chief Executive Officer, Director
Thank you.
Thank you, everybody, and welcome and thanks for coming to learn more about Laramar. We're excited to be here today.
These are our forward-looking statements. I'm not going to go through them, obviously. So, let me tell you a little bit about Friedrich's Axis.
Henry Jiang;Carole Ben;Maimon
JPMorgan Chase & Co - Analyst;Larimar Therapeutics Inc -
Sorry.
Sorry about that. It's okay.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot